Abstract
AbstractMelatonin, a hormone secreted during darkness, plays a key role in various physiological responses including regulation of circadian rhythms, sleep homeostasis, retinal neuromodulation, and vasoactivity. Its neuroprotective properties, as well as regulatory effects on circadian disturbances, revalorize melatonin's benefits as a therapeutic substance in symptomatic treatment of neurodegenerative diseases, especially Alzheimer's disease (AD) with its complex neuropathological changes and clinical symptoms related to circadian rhythm alterations. This brief review summarizes the current state of melatonin research with emphasis on its neuroprotective role in neurodegeneration, particularly with regard to melatonin's putative effects in the disease process of AD. Drug Dev. Res. 56:482–490, 2002. © 2002 Wiley‐Liss, Inc.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
